drugset / Trial / NCT05312476
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.
Timeline
- Start
- 2026-05-26
- Primary completion
- 2026-05-28
- Completion
- 2026-05-28
Outcome
Outcome not reported
Stopped: “The study did not initiate because manufacturing of the CAR-T product failed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets | Cell therapy | 1e+06 cells/kg | — |
| Subject | Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets | Cell therapy | 3e+06 cells/kg | — |
| Subject | Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets | Cell therapy | 6e+06 cells/kg | — |